Preclinical Models of Anal Cancer Combined-Modality Therapy

Area of Science:

• Oncology
• Preclinical Cancer Models
• Drug Discovery

Background:

• Anal cancer treatment options have seen minimal advancement in four decades.
• There is a critical need for innovative therapeutic strategies.
• Preclinical models are essential for evaluating new anal cancer treatments.

Purpose of the Study:

• To develop and validate two distinct preclinical models for anal cancer.
• To assess the efficacy of combined-modality therapy (CMT) and a novel drug (LY3023414) in these models.
• To provide a foundation for future research into novel anal cancer therapies.

Main Methods:

• An in vivo model using transgenic K14E6/E7 mice treated with carcinogens to induce anal tumors.
• An ex vivo model utilizing K14E6/E7 mouse anal spheroids, with and without Pik3ca mutations.
• Treatment groups included no treatment control, CMT, LY3023414 (LY3) alone, and CMT + LY3.

Main Results:

• Combined-modality therapy (CMT) significantly increased survival in the in vivo anal cancer model compared to controls (P=0.0392).
• In the ex vivo model, CMT and CMT + LY3 significantly reduced spheroid diameter compared to vehicle (P≤0.0001).
• LY3 alone significantly decreased spheroid size in K14E6/E7 spheroids without mutation (P=0.0004).

Conclusions:

• Proof of concept for two novel preclinical models for anal cancer treatment.
• These models facilitate the testing of new therapeutic agents and combinations.
• The study supports further investigation into CMT and LY3 for anal cancer treatment.